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Background
Spinocerebellar ataxia type 7 (SCA7) is one of nine neuro-
degenerative disorders caused by expanded polyglutamine
domains [1]. Aggregation of the different polyglutamine
(polyQ) expanded disease proteins have been linked to the
toxicity in these disorders [1]. We and others have shown
that polyQ expanded proteins can be degraded by autop-
hagy [2], and pharmacological activation of this pathway
has hence been suggested as a therapeutic approach for
these disorders. However, lately increasing evidence indi-
cating that autophagy dysfunction occurs in several neuro-
degenerative disorders has emerged and raised concerns
regarding using stimulation of this pathway as a therapeu-
tic approach [3]. The aim of this study was to determine if
and by which molecular mechanism(s) the expanded
SCA7 disease protein ataxin-7 (ATXN7) affects the autop-
hagic process.
Materials and methods
Inducible control and SCA7 models expressing full-length
ATXN7 with 10 (FLQ10) or 65 glutamines (FLQ65) were
used. The autophagic activity was analyzed by measuring
the p62 level and by monitoring the LC3 levels in the pre-
sence or absence of the lysosomal inhibitor bafilomycin A.
Protein aggregation was analyzed by the filter trap method
and protein-protein interactions by co-immunoprecipitation
and western blot. Cellular toxicity was determined by
the WST-1 assay.
Results
We found that mutant ATXN7 causes autophagic dys-
function by altering the cytoplasmic activity of p53 result-
ing in an increased p53-FIP200 interaction, co-aggregation
of p53-FIP200 with mutant ATXN7 and ultimately disrup-
tion of the key autophagy regulating FIP200-ULK1 com-
plex. Furthermore, we show that treatment with a p53
inhibitor, or a blocker of ATXN7 aggregation, can restore
the soluble levels of FIP200, as well as increase the autop-
hagic activity and reduce mutant ATXN7 toxicity.
Conclusions
We have identified a novel p53-mediated mechanism by
which aggregating polyQ disease proteins can disrupts
autophagic activity and showed that this inhibition con-
tributes to polyQ toxicity. An increased understanding
of the molecular mechanism by which autophagy inhibi-
tion occurs in neurodegenerative disease is of importance
if safe and efficient therapeutic approaches based on
autophagy stimulation should be developed.
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